C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $165.83 million. The enterprise value is $9.34 million.

Market Cap	165.83M
Enterprise Value	9.34M

Important Dates

The last earnings date was Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

C4 Therapeutics has 71.17 million shares outstanding. The number of shares has increased by 18.67% in one year.

Current Share Class	71.17M
Shares Outstanding	71.17M
Shares Change (YoY)	+18.67%
Shares Change (QoQ)	+0.24%
Owned by Insiders (%)	3.45%
Owned by Institutions (%)	66.18%
Float	50.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.61
Forward PS	12.77
PB Ratio	0.91
P/TBV Ratio	0.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.36.

Current Ratio	5.06
Quick Ratio	4.87
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.99% and return on invested capital (ROIC) is -27.97%.

Return on Equity (ROE)	-52.99%
Return on Assets (ROA)	-22.80%
Return on Invested Capital (ROIC)	-27.97%
Return on Capital Employed (ROCE)	-49.04%
Revenue Per Employee	$311,273
Profits Per Employee	-$1.01M
Employee Count	110
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.

Income Tax	131,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -59.27% in the last 52 weeks. The beta is 2.98, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	2.98
52-Week Price Change	-59.27%
50-Day Moving Average	1.89
200-Day Moving Average	2.77
Relative Strength Index (RSI)	56.00
Average Volume (20 Days)	1,712,789

Short Selling Information

The latest short interest is 4.66 million, so 6.54% of the outstanding shares have been sold short.

Short Interest	4.66M
Short Previous Month	4.07M
Short % of Shares Out	6.54%
Short % of Float	9.31%
Short Ratio (days to cover)	3.07

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $34.24 million and -$111.58 million in losses. Loss per share was -$1.58.

Revenue	34.24M
Gross Profit	-83.38M
Operating Income	-123.62M
Pretax Income	-106.59M
Net Income	-111.58M
EBITDA	-121.63M
EBIT	-123.62M
Loss Per Share	-$1.58

Full Income Statement

Balance Sheet

The company has $214.55 million in cash and $62.92 million in debt, giving a net cash position of $160.05 million or $2.25 per share.

Cash & Cash Equivalents	214.55M
Total Debt	62.92M
Net Cash	160.05M
Net Cash Per Share	$2.25
Equity (Book Value)	174.06M
Book Value Per Share	2.45
Working Capital	180.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$87.41 million and capital expenditures -$168,000, giving a free cash flow of -$87.58 million.

Operating Cash Flow	-87.41M
Capital Expenditures	-168,000
Free Cash Flow	-87.58M
FCF Per Share	-$1.23

Full Cash Flow Statement

Margins

Gross Margin	-243.52%
Operating Margin	-361.03%
Pretax Margin	-325.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.67%
Shareholder Yield	-18.67%
Earnings Yield	-65.87%
FCF Yield	-51.70%

Analyst Forecast

The average price target for C4 Therapeutics is $8.00, which is 243.35% higher than the current price. The consensus rating is "Buy".

Price Target	$8.00
Price Target Difference	243.35%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	114.32%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

C4 Therapeutics has an Altman Z-Score of -2.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.44
Piotroski F-Score	3